The CLSI 2024 updates introduce crucial revisions in antimicrobial susceptibility testing (AST), breakpoints, and treatment strategies. Key changes include revised MIC-based testing for non-fermenters, updates in therapy for drug-resistant infections, and direct susceptibility testing from blood cultures. Implementing these guidelines ensures accurate diagnostics, optimized treatments, and improved patient outcomes.
CLSI M100; Performance Standards for Antimicrobial Susceptibility Testing
